83-2270-35　［受注停止］GENLISA SARS-CoV-2 （Covid-19） Neutralizing Antibody ELISA 1 x 96 wells　KBVH400

特徴

• Description：ELISA for the Quantitative determination of neutralizing antibody to the SARS-CoV-2 receptor binding domain （RBD） of its spike protein in human serum and plasma samples.
• Also known as the sVNT assay.
• CE IVD marked.
• This assay has been calibrated against NIBSC / WHO international standards for COVID-19.
• The kit can be used for qualitative or quantitative estimation.
• Species and isotype independent with low-to-no cross reactivity with the flu and other viral diseases.
• Detecting and quantifying neutralizing antibodies to SARS-CoV-2 offers important information in the evaluation of immune responses, development of vaccines and therapeutic drugs.
• The kit employs a blocking ELISA technique which mimics the virus neutralization process.
• Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions.
• The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin converting enzyme 2 （ACE2） protein as a host receptor through their S1B domain.
• Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion.
• SARS-CoV-2 initiates an immune response, which leads to the production of antibodies.
• These neutralizing antibodies disable host receptor interactions and prevent viral entry into the cell.
• They, therefore, also provide protection against future infection from SARS-CoV-2, as they remain in the circulatory system for months to years post infection.